# Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS)

> **NCT05986422** · PHASE2 · TERMINATED · sponsor: **Charite University, Berlin, Germany** · enrollment: 96 (actual)

## Conditions studied

- Post-COVID-19 Syndrome

## Interventions

- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT05986422
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-10-01
- **Primary completion:** 2025-03-14
- **Final completion:** 2026-02-19
- **Target enrollment:** 96 (ACTUAL)
- **Why stopped:** Following a recommendation from the Data Safety Monitoring Board (DSMB).
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05986422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05986422, "Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05986422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*